phase readout
saveNCT07457528: Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Tianjin Medical University Cancer Institute and Hospital. Phase: PHASE2. Conditions: Resectable Esophageal Squamous Cell Carcinoma
view source ↗
comments(0)
5-min edit window · permanent after that